Immunotherapy given before or after surgery is increasingly used across several cancer areas. In an article published in the Journal of Internal Medicine, researchers at Karolinska Institutet present ...

SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant pembrolizumab induced pathologic complete response in 71% of patients with desmoplastic melanoma.

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among ...

Of 30 patients with resectable stage III melanoma treated with neoadjuvant nivolumab and relatlimab, 87% were alive and 80% remained disease-free after 4 years. Almost every patient who achieved a ...

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

Interim results from the phase 2 NESCIO trial suggest combination neoadjuvant immunotherapy has efficacy in locally advanced clear cell renal cell carcinoma. Neoadjuvant combinations of ipilimumab or ...

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, discussed how the standard of care for melanoma is evolving. For patients diagnosed with desmoplastic melanoma, the road to ...